These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31558473)

  • 21. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
    Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
    Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
    Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 25. The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib.
    Ling Y; Xiong X; Luo J; Zou Q; Chen P; Pan L; Long M; Feng H; Ouyang W
    Front Endocrinol (Lausanne); 2023; 14():1200932. PubMed ID: 37534207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
    Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
    BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.
    Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K
    Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma.
    Danilovic DL; Lima EU; Domingues RB; Brandão LG; Hoff AO; Marui S
    Eur J Endocrinol; 2014 Apr; 170(4):619-25. PubMed ID: 24468978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
    Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
    Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial.
    Huillard O; Jouinot A; Tlemsani C; Brose MS; Arrondeau J; Meinhardt G; Fellous M; De Sanctis Y; Schlumberger M; Goldwasser F
    Thyroid; 2019 Dec; 29(12):1820-1827. PubMed ID: 31860408
    [No Abstract]   [Full Text] [Related]  

  • 34. Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.
    Blair HA; Plosker GL
    Target Oncol; 2015 Mar; 10(1):171-8. PubMed ID: 25742918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.
    Paz-Ares L; Hirsh V; Zhang L; de Marinis F; Yang JC; Wakelee HA; Seto T; Wu YL; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong TJ; Peña C; Smit EF; Mok TS
    J Thorac Oncol; 2015 Dec; 10(12):1745-53. PubMed ID: 26743856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
    Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
    Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
    Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib in metastatic thyroid cancer.
    Capdevila J; Iglesias L; Halperin I; Segura A; Martínez-Trufero J; Vaz MÁ; Corral J; Obiols G; Grande E; Grau JJ; Tabernero J
    Endocr Relat Cancer; 2012 Apr; 19(2):209-16. PubMed ID: 22285864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
    Lebellec L; Bertucci F; Tresch-Bruneel E; Bompas E; Toiron Y; Camoin L; Mir O; Laurence V; Clisant S; Decoupigny E; Blay JY; Goncalves A; Penel N
    Oncotarget; 2016 Nov; 7(45):73984-73994. PubMed ID: 27659533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.